NCT00409305已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Subjects
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- OBEcure Ltd.
- 入组人数
- 280
- 试验地点
- 36
- 主要终点
- To examine the effect of betahistine on body weight in obese subjects
研究概览
简要总结
The purpose of this study is to examine the effect that betahistine has on body weight in obese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed written informed consent;
- •Male or female subjects 18 to 65 years of age;
- •Is obese with a BMI greater than or equal to 30 kg/m2 to less than or equal to 40 kg/m2;
- •Has been obese for at least 1 year prior to screening; and
- •If female, is nonlactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to randomization or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration.
排除标准
- •Has obesity of known endocrine origin (e.g., Cushing's disease, Addison's disease, hypothalamic tumor);
- •Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics (e.g., polydactyly) suggestive of genetic obesity (e.g., ob/ob genotype) or syndromatic obesity (e.g., Prader-Willi syndrome, Bardet Biedl syndrome);
- •Previous surgical procedures for weight loss;
- •Has had liposuction within 1 year before screening or is planning to have liposuction during the study;
- •History of bulimia or evidence of laxative abuse;
- •Has had a body weight loss of >4 kg in the 90 days prior to screening;
- •Has taken drugs capable of influencing body weight 30 days prior to screening;
- •Has recently started or plans on starting a smoking cessation program;
- •Has had a major change in daily physical activity (e.g., initiation of an exercise program) or started a weight loss program within 90 days prior to screening;
- •Is unwilling or unable to participate in a dietary program as part of the study;
- •Is <80% compliant with study medication in the single-blind placebo run-in period;
- •Has a clinically significant history or presence of any of the following conditions:
- •Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;
- •Liver disease (irrespective of transaminase concentrations);
- •Pheochromocytoma;
- •Porphyria;
- •Type 1 diabetes mellitus;
- •Type 2 diabetes mellitus on treatment other than metformin monotherapy and/or diet with HbA1c less than or equal to 8%;
- •Severe type 2 diabetes with history of ketoacidosis or diabetic ulcers, or presence of retinopathy, neuropathy, or nephropathy;
- •Renal insufficiency defined as a serum creatinine greater than or equal to 1.5 mg/dL (133 µmol/L) at screening;
- •Malignant disease within 5 years of screening;
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x ULN;
- •Thyroid-stimulating hormone (TSH) outside of the normal range;
- •Plans on having any surgery (elective or otherwise) during the course of the study;
- •Has uncontrolled hypertension (sitting blood pressure >160/95 mmHg at screening or randomization), uncontrolled hyperlipidemia (triglycerides [TG] greater than or equal to 400 mg/dL or low-density lipoprotein cholesterol [LDL-C] >160 mg/dL), or uncontrolled diabetes (HbA1c >8%);
- •History of asthma;
- •History of peptic ulcers;
- •History of HIV;
- •History of undiagnosed allergy, severe allergy, or drug allergy, including history of anaphylaxis, angioedema, bronchospasm, or urticaria;
- •Has clinical laboratory test values (chemistry, hematology, or urinalysis) judged to be clinically significant by the investigator;
- •Has a physical examination or electrocardiogram (ECG) with significant abnormalities, as judged by the investigator;
- •Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion could cause the subject to be noncompliant with study procedures;
- •Has hypersensitivity to betahistine;
- •Has psychiatric or neurological disorders requiring chronic medications (e.g., antidepressants), subjects are to be unlikely to have a major depressive episode (score of lees than or equal to 8) on The Harvard Department of Psychiatry and National Depression Screening Day Scale (THE HANDS) (See Appendix E);
- •Chronic or as needed use of antihistamines;
- •Has not been on a stable treatment regimen with any of the following medications for a minimum of 90 days prior to screening:
- •Hormone replacement therapy;
- •Oral contraceptives;
- •Antihypertensive agents;
- •Metformin;
- •Lipid-lowering agents; or
- •Thyroid replacement therapy;
- •Has been treated over the past 60 days, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications;
- •All prescription or over-the-counter agents taken for the purpose of weight reduction, including (but not limited to) the following anti obesity agents:
- •Prescription drugs such as orlistat, sibutramine, and phentermine; or
- •Over-the-counter antiobesity agents (e.g., herbal supplements or other alternative remedies such as Cortislim, Dexatrim, Acutrim);
- •Psychotropic/neurological agents including the following:
- •Antipsychotic agents (e.g., olanzapine, clozapine, risperidol, lithium, etc.).
- •Antiepileptic agents (e.g., Topamax®, Zonegran®, valproate, carbamazepine); or
- •Antidepressant agents including the following: monoamine oxidase inhibitors, bupropion (Wellbutrin®, Zyban®), tricyclic antidepressants, and tetracyclic antidepressants; and selective serotonin reuptake inhibitors (e.g., Prozac®, Paxil®, Zoloft®, etc.);
- 另有 9 项未显示
结局指标
主要结局
To examine the effect of betahistine on body weight in obese subjects
次要结局
未报告次要终点
研究者
研究点 (36)
Loading locations...
相似试验
已完成
2 期
Efficacy Study of Betahistine on Body Weight in Obese Female SubjectsObesityNCT00748436OBEcure Ltd.187
尚未招募
3 期
Betahistine and Weight- Related and Metabolic Measures in schizophrenic Patients Treated with Olanzapin or RisperidoneSchizophreniaIRCT20191223045870N1Mashhad University of Medical Sciences56
撤回
4 期
A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior CirculationVertigoNCT00474409Eisai Inc.
已完成
不适用
the Effect of Weight Bearing Status on Healing and Pain Outcomes After Surgery for Osteochondral Defects of the AnkleOsteochondritis Dissecans of Ankle and Joints of FootNCT01405664Nova Scotia Health Authority68
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese SubjectsObesityNCT00909766Bristol-Myers Squibb113